ClinicalTrials.gg
TerminatedNCT00642603Updated Aug 26, 2026Results posted

A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer

A Phase 2 interventional study of capecitabine [Xeloda] and capecitabine [Xeloda] in Colorectal Cancer, sponsored by Hoffmann-La Roche. Terminated at 76 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Enrollment
107th of 183
41 · median 50
Started
2008
with 15 others
Phase 2
110 of 206
12 open now
Registered
108th of 206
by date
Lead sponsor
11 of 206
Hoffmann-La Roche

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 107th largest by enrollment of the 183 interventional ones that give a count, is one of 16 that started in 2008, is one of 110 in phase 2, and was the 108th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 2-weekly cycles of treatment with either: 1) Xeloda, Avastin and oxaliplatin; or 2) Xeloda, Avastin and irinotecan. After 9 cycles, patients continued to receive maintenance treatment with Xeloda + Avastin. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥18 years of age
  • confirmed adenocarcinoma of colon or rectum, with unresectable or locally advanced disease
  • ≥1 measurable target lesion
  • Ambulatory, with an (ECOG) performance status of ≤1

Exclusion criteria

Exclusion Criteria:

  • Prior systemic therapy for advanced or disease
  • History of another within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of the cervix
  • cardiovascular disease
  • Current or recent use of full dose oral warfarin or full dose parenteral anticoagulants or thrombolytic agents
  • Chronic daily treatment with >325 mg/day aspirin
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    XELOX + bevacizumab (Q2W)

    Drug: capecitabine [Xeloda] · Drug: bevacizumab [Avastin] · Drug: oxaliplatin

  • Experimental
    XELIRI + bevacizumab (Q2W)

    Drug: capecitabine [Xeloda] · Drug: bevacizumab [Avastin] · Drug: irinotecan

Interventions

  • 1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle

  • 1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle

  • 5 mg/kg taken intravenously on Day 1 of each 2 week cycle

  • 85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles

  • 135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) in U.S. Patients Only

    PFS was defined as the time from the date of randomization to the first documented occurrence of disease progression or death due to any cause.

    Time frame: From first patient enrolled up to approximately 48 months

07

Results

Posted Jun 23, 2011
Limitations and caveats
This study was terminated early because interim data from a predecessor study invalidated the scientific rationale that provided justification for the conduct of this study. Efficacy analyses were not performed.

Participant flow

Participant flow — Overall Study
MilestoneXELOX + Bevacizumab (Q2W)XELIRI + Bevacizumab (Q2W)
Started2120
Safety population1920
Completed02
Not completed2118

Outcome measures

PrimaryProgression-free Survival (PFS) in U.S. Patients Only

PFS was defined as the time from the date of randomization to the first documented occurrence of disease progression or death due to any cause.

Time frame:
From first patient enrolled up to approximately 48 months
Reported as:
Number · months

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
XELOX + Bevacizumab (Q2W)—4/19 (21.1%)17/19 (89.5%)
XELIRI + Bevacizumab (Q2W)—7/20 (35%)19/20 (95%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventXELOX + Bevacizumab (Q2W)XELIRI + Bevacizumab (Q2W)
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/192/20
Clostridium Difficile ColitisInfections and infestations1/190/20
Hypertrophic CardiomyopathyCardiac disorders1/190/20
RhabdomyolysisMusculoskeletal and connective tissue disorders1/190/20
DiarrhoeaGastrointestinal disorders0/191/20
Intestinal ObstructionGastrointestinal disorders0/191/20
PneumoniaInfections and infestations0/191/20
AstheniaGeneral disorders and administration site conditions0/191/20
Lacunar InfarctionNervous system disorders0/191/20
AngioedemaSkin and subcutaneous tissue disorders0/191/20
Most frequent other events
Showing 10 of 106
Most frequent other events
EventXELOX + Bevacizumab (Q2W)XELIRI + Bevacizumab (Q2W)
DiarrhoeaGastrointestinal disorders9/1911/20
NauseaGastrointestinal disorders6/1911/20
Neuropathy PeripheralNervous system disorders9/190/20
FatigueGeneral disorders and administration site conditions7/197/20
Abdominal PainGastrointestinal disorders1/196/20
AnorexiaMetabolism and nutrition disorders5/191/20
VomitingGastrointestinal disorders4/195/20
RashSkin and subcutaneous tissue disorders4/190/20
ConstipationGastrointestinal disorders3/194/20
DehydrationMetabolism and nutrition disorders3/194/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)XELOX + Bevacizumab (Q2W)XELIRI + Bevacizumab (Q2W)Total
Mean63.9 ± 12.0660.6 ± 9.8962.3 ± 11.04
Sex: Female, Male
Sex: Female, Male(Participants)XELOX + Bevacizumab (Q2W)XELIRI + Bevacizumab (Q2W)Total
Female8715
Male131326
08

Study locations

76 sites
  • PARK Springs, Arizona 71913, United States
  • Sedona, Arizona 86336, United States
  • Tucson, Arizona 85712, United States
  • Anaheim, California 92801, United States
  • Colton, California 92324, United States
  • Greenbrae, California 94904, United States
  • Loma Linda, California 92354, United States
  • Modesto, California 95355, United States
  • Montebello, California 90640, United States
  • Pomona, California 91767, United States
  • Sacramento, California 95816, United States
  • Norwich, Connecticut 06360, United States
  • Waterbury, Connecticut 06708, United States
  • Lake Worth, Florida 33431, United States
  • Miami Shores, Florida 33179, United States
  • New Port Richey, Florida 34655, United States
  • Ocala, Florida 34474, United States
  • Ocoee, Florida 34761, United States
  • Marietta, Georgia 30060, United States
  • Niles, Illinois 60714, United States
  • Paducah, Kentucky 42002, United States
  • Alexandria, Louisiana 71301, United States
  • Baltimore, Maryland 21204, United States
  • Baltimore, Maryland 21237, United States
  • Westminster, Maryland 21157, United States
  • Pittsfield, Massachusetts 01201, United States
  • Worcester, Massachusetts 01608, United States
  • Kalamazoo, Michigan 49048, United States
  • Duluth, Minnesota 55805, United States
  • Jefferson City, Missouri 65109, United States
  • Great Falls, Montana 59405, United States
  • Las Vegas, Nevada 89109, United States
  • Neptune City, New Jersey 07754, United States
  • Albuquerque, New Mexico 87102, United States
  • Albuquerque, New Mexico 87131-5636, United States
  • Santa Fe, New Mexico 87505, United States
  • Brooklyn, New York 11219, United States
  • Huntington Station, New York 11746, United States
  • Durham, North Carolina 27710, United States
  • Hickory, North Carolina 28602, United States
  • Canton, Ohio 44718, United States
  • Eugene, Oregon 97401-8122, United States
  • Ephrata, Pennsylvania 17522, United States
  • Langhorne, Pennsylvania 19047, United States
  • Philadelphia, Pennsylvania 19102, United States
  • Scranton, Pennsylvania 18510, United States
  • Charleston, South Carolina 29403-5740, United States
  • Charleston, South Carolina 29406, United States
  • Florence, South Carolina 29506, United States
  • Sumter, South Carolina 29150, United States
  • Chattanooga, Tennessee 37404, United States
  • Cookeville, Tennessee 38501, United States
  • Nashville, Tennessee 37203, United States
  • Amarillo, Texas 79106, United States
  • Arlington, Texas 76014, United States
  • Beaumont, Texas 77702-1449, United States
  • Bedford, Texas 76022, United States
  • Carrollton, Texas 75010, United States
  • Corpus Christi, Texas 78412, United States
  • Dallas, Texas 75230, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75237, United States
  • Fort Worth, Texas 76104, United States
  • Garland, Texas 75042, United States
  • Lewisville, Texas 75067, United States
  • Mesquite, Texas 75150, United States
  • Paris, Texas 75460, United States
  • Round Rock, Texas 78681, United States
  • San Antonio, Texas 78229, United States
  • Southlake, Texas 76092, United States
  • Sugarland, Texas 77479, United States
  • Waco, Texas 76712, United States
  • Webster, Texas 77598-4420, United States
  • Salt Lake City, Utah 84106, United States
  • Christiansburg, Virginia 24073, United States
  • Seattle, Washington 98133, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2008
First posted
Mar 25, 2008
Start
May 2008
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Jun 23, 2011
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00642603
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 25, 2008
Start date
May 2008
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Jun 23, 2011
Last update
Aug 26, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Irinotecan

Start the discussion